Overview

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Status:
Completed
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether microbiome modulation and an experimental reduction in plasma LPS concentration improve inflammation and insulin action in insulin resistant (obese and T2DM) subjects.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
American Diabetes Association
Treatments:
Sevelamer